Edwards Lifesciences Lunch Symposia

Edwards Lifesciences Symposia

Explore cutting-edge topics at our two lunch symposia. Gain insights from leading experts and engage in impactful discussions. Be sure to check out the full agenda below and save the dates in your calendar!

Thursday 09 Oct 2025

Thursday 09 Oct 2025 | 09:00 - 18:30 |

A new horizon in aortic root disease management

Explore the latest in aortic root disease management, from surgical innovations like Valsalva vs. straight conduits to the integration of new technologies and pre-assembled valved conduits. Gain practical insights to enhance outcomes in this evolving field.

Moderators: Ruggero De PaulisItaly.

Current landscape and challenges in aortic root disease management

Laurent De Kerchove
Belgium

Valsalva vs. Straight conduit: Technical rationale and clinical impact

Ruggero De Paulis
Italy

Integrating evidence-based technology in aortic root disease management

Nimesh Desai
USA

Integrating evidence-based technology in aortic root disease management

J. Bavaria
USA

Discussion

Friday 10 Oct 2025

Lifetime Management in Light of the 2025 ESC/EACTS Guidelines

Explore how the new guidelines are redefining lifetime management of heart valve disease. This symposium offers practical insights into next-gen bioprosthesis, durable treatment strategies, and real-world case discussions to support long-term patient care.

Moderators: Christian CarranzaDenmark and Michael BorgerGermany.

Impact of the 2025 ESC/EACTS Guidelines on heart valve disease treatment

Michael Borger
Germany

Next-generation bioprostheses in SAVR: A propensity-matched 8-year outcome study

Vinod Thourani
USA

Designing durable pathways in the management of aortic valvular heart disease

Jessica Forcillo
Canada

Case-based exploration of modern lifetime valve strategies

Christian Carranza
Denmark

Discussion

Seeking continuous learning?

Download Edwards Masters App.

A professional digital education platform for cardio-thoracic surgeons. Your go-to resource for staying at the forefront.

Clinical data on valves with RESILIA tissue up to 7-year follow-up have been published, with additional follow-up of up to 10 years in process.

Reference: Beaver T, Bavaria JE, Griffith B, et al. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis. J Thorac Cardiovasc Surg. 2024 Sep;168(3):781-791.

Expert opinions, advice and all other information represent contributor’s views and not necessarily those of Edwards Lifesciences.

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult https://eifu.edwards.com where applicable).